29,655 Shares in uniQure N.V. $QURE Purchased by Havemeyer Place LP

Havemeyer Place LP purchased a new position in uniQure N.V. (NASDAQ:QURE) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 29,655 shares of the biotechnology company’s stock, valued at approximately $710,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC increased its stake in uniQure by 22.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock worth $259,422,000 after buying an additional 819,444 shares during the period. Aberdeen Group plc increased its stake in uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares during the period. Franklin Resources Inc. increased its stake in uniQure by 23.9% in the 3rd quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after buying an additional 383,066 shares during the period. Sofinnova Investments Inc. increased its stake in uniQure by 185.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after buying an additional 1,012,585 shares during the period. Finally, Jennison Associates LLC increased its stake in uniQure by 37.2% in the 4th quarter. Jennison Associates LLC now owns 1,371,190 shares of the biotechnology company’s stock worth $32,813,000 after buying an additional 371,706 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $15.00 to $60.00 in a report on Monday, March 9th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Leerink Partners reiterated an “outperform” rating and set a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Finally, Chardan Capital increased their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

uniQure Stock Up 2.1%

NASDAQ:QURE opened at $27.00 on Tuesday. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The stock has a market capitalization of $1.70 billion, a P/E ratio of -7.76 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The company’s 50-day simple moving average is $21.62 and its 200-day simple moving average is $21.78.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. On average, equities analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Insider Activity at uniQure

In related news, Director Jack Kaye sold 2,645 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $30.01, for a total value of $79,376.45. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $613,374.39. This trade represents a 11.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 45,000 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the completion of the transaction, the insider directly owned 169,669 shares of the company’s stock, valued at $4,251,905.14. The trade was a 20.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.65% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.